



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/724,575	11/28/2000	Dale B. Schenk	15270J-005912US	6096

7590

03/27/2002

Nina M. Ashton
Elan Pharmaceuticals, Inc.
800 Gateway Boulevard
South San Francisco, CA 94080

EXAMINER

TURNER, SHARON L

ART UNIT	PAPER NUMBER
----------	--------------

1647

DATE MAILED: 03/27/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/724,575

Applicant(s)

Schenk

Examiner
Sharon L. Turner, Ph.D.

Art Unit
1647



— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) ☒ Responsive to communication(s) filed on 12-11-01

2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.

3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) ☒ Claim(s) 1-57 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) ☐ Claim(s) _____ is/are allowed.

6) ☐ Claim(s) _____ is/are rejected.

7) ☐ Claim(s) _____ is/are objected to.

8) ☒ Claims 1-57 are subject to restriction and/or election requirements.

Application Papers

9) ☐ The specification is objected to by the Examiner.

10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.

12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) ☐ All b) ☐ Some* c) ☐ None of:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. _____.

3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) ☐ Notice of References Cited (PTO-892)

18) ☐ Interview Summary (PTO-413) Paper No(s). _____

16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)

19) ☐ Notice of Informal Patent Application (PTO-152)

17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____

20) ☐ Other: _____

Art Unit: 1647

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-10, drawn to a pharmaceutical composition comprising an agent effective to induce an immune response against an amyloid component, classified in class 530, subclass 350.
 - II. Claims 11-25, drawn to a method of preventing or treating a disorder characterized by amyloid deposition by administering an agent effective to induce an immune response against an amyloid component classified in class 514, subclass 12.
 - III. Claims 26-28 drawn to a method of determining the prognosis of a patient by measuring immunoreactivity of the patient's serum against amyloid component, classified in class 424, subclass 9.2.
 - IV. Claims 29-39, 42-43, drawn to a method of preventing or treating a disorder characterized by amyloid deposition by administering an antibody that specifically binds to an amyloid component, classified in class 424, subclass 130.1.
 - V. Claims 40-41, drawn to a method of preventing or treating a disorder characterized by amyloid deposition by administering a nucleic acid encoding an antibody that specifically binds to an amyloid component, classified in class 514, subclass 44.
 - VI. Claims 44-57, drawn a pharmaceutical composition comprising an antibody that specifically binds to an amyloid component, classified in class 530, subclass 389.3.

Art Unit: 1647

treating a disorder by using different pharmaceutical compositions, while the method of invention III determines the prognosis of a patient.

7. Inventions I and III-V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the methods of Groups III-IV neither use nor produce the agent of group I.

8. Inventions VI and II-III, V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the methods of Groups II-III, and IV neither use nor produce the antibody of group VI.

Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has prima facie shown a serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

Additional Restriction Requirement

9. The claims of Groups I-VI are drawn to a multitude of amyloid components, agents, fibril components, as recited in claims 3, 5-6, 13, 15, 34-35 and 49-50. This constitutes a recitation of an implied, mis-joined Markush group that contain multiple, independent and distinct inventions. Each of the amyloid components, agents and fibril components are independent and distinct because no

Art Unit: 1647

common structural or functional properties are shared. Accordingly, these claims are subject to restriction under 35 U.S.C. 121.

10. Upon election of one of Groups I-VI, Applicant is additionally required to elect a single amyloid component, i.e Applicant must elect one amyloid component, agent and fibril components from each of claims 3, 5-6, 13, 15, 34-35 and 49-50, (depending on the inventive Group, which is elected). This requirement is not to be considered as a requirement of an election of species, since each of the compounds recited in alternative from is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

11. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

13. Any inquiry of a general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for Group 1600 is (703) 308-4242.

Art Unit: 1647

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharon L. Turner, Ph.D. whose telephone number is (703) 308-0056. The examiner can normally be reached on Monday-Friday from 8:00 AM to 4:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (703) 308-4623.

Sharon L. Turner, Ph.D.
March 25, 2002

Gary L. Kunz
GARY L. KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

US 0972457507P1



Creation date: 09-10-2003
Indexing Officer: TLEGESSE - TSEGAYE LEGESSE
Team: OIPEBackFileIndexing
Dossier: 09724575

Legal Date: 09-26-2002

No.	Doccode	Number of pages
1	LET.	3
2	A...	4
3	XT/	1

Total number of pages: 8

Remarks:

Order of re-scan issued on